Following Health Canada, Canada's Drug Agency evaluates the pharmacoeconomics of a new product. As part of that, it also evaluates clinic evidence that has already been evaluated by Health Canada in order to make the decision that a new product is safe and effective. There is a duplication there.
The pharmacoeconomics is also undertaken by the industry. The challenge is that the pharmacoeconomic model that Canada's Drug Agency applies at the moment has not been updated in a long time, and it uses comparators that are really quite outdated in terms of the value of a human life. It also does not take into account the value of a new product, a new medicine, in terms of saving lives, in terms of keeping people productive and participants in our economy. There's an imbalance in terms of looking strictly at the cost.
Then, the pan-Canadian Pharmaceutical Alliance starts its activities only once Canada's Drug Agency has made its decision and has made a recommendation. If the recommendation from Canada's Drug Agency is a negative one, the industry has invested all of this investment to no avail, because it's very difficult to start the process again. Then, the negotiations—